Shares of the company are trading at $1.46 quite a bit higher than the 50 day moving average of $1.13 and which is well above the 200 day moving average of $1.12. The 50 day moving average was up $0.33 and the 200 day average went up by +30.17%. Alcobra Ltd. – Ordinary Shares shares had a trading volume of 5,228K on Tuesday. Trading volume was up 6,463.75% over the stocks average daily volume.
Investors are more bullish on shares of the company lately if you take into consideration the motion in short interest. The company recorded a fall in short interest of -5.95% between September 15, 2017 and September 29, 2017. Short shares decreased from 876,447 to 824,301 over that timeframe. Days to cover decreased -8.0 to 3.0 and the short interest percentage is 0.03% as of September 29.
The following firms have recently changed their position in ADHD. As of quarter end Goldman Sachs Group Inc had sold 17,791 shares trimming its position 39.5%. The value of the investment in Alcobra Ltd. – Ordinary Shares went from $51,000 to $30,000 a change of $21,000 quarter to quarter. Kingdon Capital Management, L.l.c. trimmed its ownership by selling 50,479 shares a decrease of 14.4% as of 06/30/2017. Kingdon Capital Management, L.l.c. owns 300,945 shares valued at $337,000. The total value of its holdings decreased 16.0%.
Panagora Asset Management Inc expanded its investment by buying 265,202 shares an increase of 142.1% in the quarter. Panagora Asset Management Inc currently owns 451,781 shares worth $506,000. The value of the position overall is up by 137.6%. As of the end of the quarter Two Sigma Investments, Lp had acquired a total of 700 shares growing its stake by 3.2%. The value of the investment in ADHD decreased from $25,000 to $25,000 a change of 0.0% quarter over quarter.
On October 9 the stock rating was upgraded to “Speculative Buy” from “Hold” with a current price target of $2.00 by WBB Securities.
As of the last earnings report the EPS was $-0.76 and is expected to be $-0.77 for the current year with 27,562,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.22 and the next full year EPS is projected to be $-0.68.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel..